Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma | MicrobiomeTrials← Back to trialsNCT06876142
Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma
SUSPENDEDPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2026-06-14Est. Completion: 2033-01-01
Enrollment target: 54 participants Locations- National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Other microbiome trials you might be interested in
Myeloma Multiple
The BELAMI trial is an open label, multicenter, phase 2 study for patients with MM who relapsed following BCMA-directed …
Amiens, FranceEst. completion Jan 1, 2028
Malignancy, HematologicNeoplasms, HematologicNeoplasms, HematopoieticBlood CancerHematological NeoplasmsHematopoietic MalignanciesDysmyelopoietic SyndromesHematopoetic Myelodysplasia
Myeloid Leukemia, Acute
Nonlymphoblastic Leukemia, Acute
Leukemia, Lymphocytic, Acute
Background:
Blood cancers (such as leukemias) can be hard to treat, especially if they have mutations in the TP53 or RA…
Bethesda, United StatesEst. completion Apr 30, 2029